Natural Capsules Peer Comparison

NSE: NATCAPSUQ | BSE: 524654

₹178.58

₹6.04 (3.50%)

As on 17-Sep-2026IST

Market cap

₹183 Cr

Revenue (TTM)

₹191 Cr

P/E Ratio

P/B Ratio

0.9

Div. Yield

0 %

Edit

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	183	19,728	18,725	18,150	18,373
Revenue (₹ Cr)	191	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	-24.83	678.07	273.51	666.92	735.15
Net Margin (%)	-12.77	28.10	16.19	20.60	26.88
RoE (%)	-9.60	19.73	11.15	18.75	19.16
Price to Earnings	--	29.65	62.98	28.19	24.99
Price-To-Book	0.85	5.37	6.97	4.50	4.17

Income Statement (₹ Cr)

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	190.71	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	194.44	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	191.47	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	-0.76	796.58	478.55	1,139.61	941.63
Depreciation	17.26	78.10	126.01	281.06	57.58
EBIT	-18.02	718.48	352.55	858.55	884.05
Interest	13.39	0.88	52.11	190.64	7.69
Other Income	3.73	125.96	7.37	7.45	165.62
Exceptional Items	0.00	0.00	12.16	-17.24	-49.16
Profit before Tax	-27.69	843.56	319.96	658.12	992.82
Provision for Tax	-2.86	165.49	46.45	-8.80	257.67
Profit after Tax	-24.83	678.07	273.51	666.92	735.15

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	221.64	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	3.30	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	56.71	28.74	266.35	1,392.75	91.50
Current Liabilities	132.73	385.94	848.06	2,077.10	627.48
Total Liabilities	424.16	4,037.51	3,705.61	7,246.72	4,921.88

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	282.39	1,291.22	2,525.44	5,617.77	770.28
Current Assets	136.80	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	424.16	4,037.51	3,705.61	7,246.72	4,921.88
Total Debt*	114.34	0.57	657.97	2,309.68	2.50
Net Current Assets	4.07	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	75.24	17.53	160.01	51.57	370.49

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	10.92	523.24	342.18	537.99	967.57
Cash Flow from Investing Activities	-10.77	-582.30	-325.92	-369.46	-561.67
Cash from Financing Activities	-0.62	-46.46	13.62	-313.53	-798.31
Net Cash Inflow / Outflow	-0.47	-105.52	29.88	-145.00	-392.41

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	-4.85	24.97	11.43	14.47	23.39
ROE (%)	-9.60	19.73	11.15	18.75	19.16
ROA (%)	-5.89	18.69	7.80	9.26	14.95
EBIT Margin (%)	-9.45	31.41	20.95	26.58	34.40
Net Margin (%)	-12.77	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	8.84	15.01	27.91	9.59	10.69
EBIT Growth (%)	-844.67	18.45	58.32	16.84	24.14
Net Profit Growth (%)	-345.97	19.61	149.56	62.68	-9.09
EPS Growth (%)	-274.80	17.73	-3.57	67.41	14.40
Book Value Growth (%)	-5.21	26.75	9.67	36.71	-0.34

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	-8.48	29.65	66.81	27.51	23.82
Price / Book Value	0.85	5.37	6.97	4.50	4.17
Dividend Yield (%)	0.00	0.31	0.06	0.00	1.87
EV/EBITDA	-386.36	23.50	40.41	17.89	16.21
Market Cap (₹ Cr)	149.97	11,439.22	6,819.66	17,980.08	21,592.90

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.25	0.00	0.07	0.24	0.00
Short term debt to equity ratio	0.20	0.00	0.16	0.12	0.00
Current Ratio	1.03	6.70	1.31	0.74	6.06
Quick Ratio	0.83	5.59	0.88	0.53	5.31
Interest Coverage	-1.07	959.59	7.14	4.45	130.11

	Natural Capsules	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	37.41	36.10	30.84	21.07	7.07
Asset Turnover	0.45	0.63	0.48	0.45	0.52
Receivable days	130.24	121.68	113.81	63.88	26.06
Inventory Days	50.48	63.83	84.76	43.27	65.95
Payable days	167.31	108.28	101.94	151.85	81.01
Cash Conversion Cycle	13.41	77.23	96.62	-44.70	11.00

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.